Idova 7
8Pages

CRM // Tachyarrhythmia Therapy //  ICD and CRT-D Engineered for first-shock success

More power – no compromises The Idova 7 Series is the only 45 joule ultra highenergy device series already able to deliver 40.5 joules with the first shock – without compromising on short charge times, small size and exceptional device longevity. The innovative Idova technology has been engineered for first-shock success and control over spontaneous VF – powerful therapy even for patients at risk of having a high DFT today or in the future. So when choosing a device capable of delivering the required shock, why not choose the most powerful one?

Are we in complete control of spontaneous VF? Despite a 10-joule safety margin and low defibrillation thresholds (DFT) of less than 15 joules at testing during implantation, first shock success rates for spontaneous rapid arrhythmias are only 83% to 93%.1,2,3 Why does an induced rapid arrythmia differ from a spontanous one? Defibrillation testing is performed in anesthetized and clinically stable patients who are lying in a supine position. In contrast, spontaneous VT/VF can occur during unstable cardiac conditions and in an upright position – when DFTs are higher. 4,5 Success rate of first...

Do you know how high your patient’s DFT is today or will be tomorrow? Multiple studies have identified many factors that are correlates of higher DFTs. Cumulatively, these factors might decrease defibrillation efficacy. Failed ATP and long episodes Antitachycardia pacing (ATP) is widely used as a first therapeutic approach in clinical practice. However, DFT levels may increase when ATP fails. As a result, the success rate of the subsequent first shock may be decreased.1 In this case, 35–37 joule shocks might not be of sufficient power anymore. 6 Unknown defibrillation efficacy When testing...

Risk factors decreasing shock efficacy Medication E.g. amiodarone7 or sildenafil 8 Heart failure Greater left-ventricular size or mass and very poor left-ventricular ejection fraction 5, 9 Patient size Big or tall patients with greater body surface area 10 High activity level Younger and active patients 5,7,9 Implantation site Right-sided implantations11

Gaining control over VF in everyday life – with or without testing Spontaneous VF and higher DFTs over a patient’s lifetime present potential risks. Why not be on the safe side? With or without testing, the powerful Idova 7 Series instills greater confidence in physicians and patients alike. The new standard for ICD and CRT-D therapy The second-generation ProMRI ® technology is a masterpiece of innovation with ultra high-energy therapy starting with the first shock – without compromising on short charge times, a comfortable small size and outstanding longevity. Designed to stop...

Idova 7 Series Wide-ranging excellence Safe access for patients to MRI examinations Small device size with excellent longevity ® BIOTRONIK Home Monitoring Heart Failure Monitor Proven early detection of asymptomatic events Comprehensive heart failure diagnostics Unique atrial diagnostics in ­ single-chamber ICDs Significant reduction of unnecessary shocks

Idova 7 ICD and CRT-D series Engineered for first-shock success Model Idova 7 VR-T Idova 7 VR-T DX Idova 7 DR-T Shock energy 45 joules stored, 40.5 joules delivered with first shock 45 joules stored, 40.5 joules delivered with first shock 45 joules stored, 40.5 joules delivered with first shock 45 joules stored, 40.5 joules delivered with first shock 45 joules stored, 40.5 joules delivered with first shock 45 joules stored, 40.5 joules delivered with first shock 45 joules stored, 40.5 joules delivered with first shock 1  ha Y-M et al., Impact of shock energy and ventricular rhythm on the...